Allyx Therapeutics, Inc.
About
Allyx Therapeutics is a clinical-stage biotechnology company developing disease-modifying oral therapies for neurodegenerative disorders. Its primary focus is on preserving and protecting synapses to slow or reverse the cognitive decline seen in conditions like Alzheimer's and Parkinson's disease. The company's strategy revolves around its lead compound, which targets the underlying cellular pathology of these diseases rather than just managing symptoms.
Company Values
The company's lead compound, ALX-001, utilizes a novel mechanism as a silent allosteric modulator of the mGluR5 receptor. This approach allows it to selectively block pathogenic signaling linked to synapse loss while preserving the normal receptor function essential for cognition, potentially offering a wider therapeutic window and fewer side effects than other modulators.